ArticleMolecular therapy. Oncology2026
Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapy.
Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synergistic Oncolytic Effect of HSVtk- and IL-15Rα-Armed Vaccinia Viruses Inducing Systemic Antitumor Immunity.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oncolytic viruses are broad-spectrum cancer immunotherapies with multiple mechanisms of action that complement other therapeutics, but concerns remain regarding intravenous (i.v.) safety, overexpression of transgenes, environmental shedding, and lack of imaging in patients. Here we describe the engineering and evaluation of an i.v. oncolytic vaccinia virus (VV) therapeutic expressing a hyperactive and selective herpes simplex virus thymidine kinase (HSV-TK.007). In the presence of i.v. or topical ganciclovir (GCV), HSV-TK.007 acted to block VV replication either systemically or topically for control of skin lesions and shedding, respectively. HSV-TK.007 expression also enabled systemic positron emission tomography-computed tomography (PET-CT) imaging of tumor-specific virus replication
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.